Document:

amrn-ex105_246.htm

Exhibit 10.5

 

AMARIN CORPORATION plc 2020 STOCK INCENTIVE PLAN

AWARD AGREEMENT

 

This AWARD AGREEMENT (the “Agreement”) is entered into and made effective as of [          ], 20[  ] between Amarin Corporation plc (the “Company”) and [          ] (the “Optionee”). The Company hereby grants to the Optionee Non-Qualified Stock Options (the “Options”) as set forth below.  Capitalized terms used and not defined herein shall have the meanings set forth in the Amarin Corporation plc 2020 Stock Incentive Plan (the “Plan”), which is incorporated by this reference in its entirety.

 

	
1.
	
Number of Non-Qualified Stock Options:  [          ]

 

	
2.
	
Per Share Purchase Price:  $[     ] (closing market price per NASDAQ on [          ], 20[  ] (provided that such Per Share Purchase Price shall not be less than the par value of the Share at any time, currently £0.50))

 

	
3.
	
Grant Date:  [          ]

	
4.
	
Date Options Become Exercisable (Vesting):  The Options shall vest in full upon the earlier of the one-year anniversary of the Grant Date or the Annual General Meeting of Shareholders in such anniversary year, subject to the Optionee’s continued service to the Company through such vesting date. Notwithstanding the above vesting schedule, the Options shall be fully vested in the event of a Change of Control (as defined in the Plan).

	
5.
	
Expiration Date:  [          ]

	
6.
	
Terms of this Award Agreement:  In the event of a conflict between the provisions of this Agreement and the Plan, except in relation to paragraph 7 below, the provisions of the Plan shall prevail. A copy of the Plan is provided herewith.

 

	
7.
	
Non-transferable:  These Options shall not be transferable by the Optionee other than by will or the laws of descent and distribution, and the Options shall be exercisable, during the Optionee’s lifetime, only by the Optionee.

 

By signing this Agreement, you agree to all of the terms and conditions described herein and in the Plan.

 

AMARIN CORPORATION plc OPTIONEE

 

By: ____________________________ Signature: ______________________________

Name: [          ]Name:[          ]

Title: [          ]amrn-ex106_247.htm

Exhibit 10.6

AMARIN CORPORATION plc 2020 STOCK INCENTIVE PLAN

DEFERRED RESTRICTED STOCK UNIT AWARD AGREEMENT

 

This AWARD AGREEMENT (the “Agreement”) is entered into and made effective as of [          ], 20[  ] by and between Amarin Corporation plc (the “Company”) and [          ] (the “Participant”).  The Company hereby grants to the Participant an award (the “Award”) of deferred restricted stock units (the “DSUs”) as set forth below. Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the Amarin Corporation plc 2020 Stock Incentive Plan (the “Plan”), which is incorporated by this reference in its entirety.    

	
1.
	
Maximum Number of DSUs:  [          ]

 

	
2.
	
Grant Date:  [          ]

 

	
3.
	
Vesting:  The DSUs shall vest pursuant to the following table, subject to the Participant’s continued service to the Company through each such vesting date:

 

		
	
Number of DSUs
	
Vesting Date

	
[          ]
	
Earlier of [          ], 20[  ] or the [    ] Annual General Meeting of Shareholders

	
[          ]
	
Earlier of [          ], 20[  ] or the [    ] Annual General Meeting of Shareholders

	
[          ]
	
Earlier of [          ], 20[  ] or the [    ] Annual General Meeting of Shareholders

Notwithstanding the above vesting schedule, the DSUs shall be fully vested in the event of a Change of Control (as defined in the Plan).

Upon vesting of each DSU, the Participant shall be entitled to a payment equal to the Fair Market Value of one Share.  The payment shall be paid to the Participant in Shares, or at the sole discretion of the Committee in cash or any combination of cash or Shares, such that the requirements of Section 580 of the Companies Act 2006 are satisfied (being that no Shares are issued for a consideration of less than their nominal value). Any such Shares may be subject to restrictions concerning their transferability and/or forfeiture as the Committee may determine. Settlement of vested DSUs pursuant to this Section 3 shall be made upon the earlier of thirty (30) days after the Participant’s Separation from Service (within the meaning of U.S. Treasury Regulation Section 1.409A-1(h)) or upon a Change of Control that qualifies as a “change in control event” within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”). This Agreement is intended to be a compliant deferred compensation plan under Section 409A and shall be administered in accordance with the requirements of Section 409A. If the Participant is a “specified employee” (as defined in Section 409A of the Code) at the time of his or her separation from service and the DSUs are settled on account of such separation from service, then the settlement shall be delayed for six months or until the Participant’s death, if earlier, to the extent required to avoid adverse taxation under Section 409A of the Code.

 

	
4.
	
Termination:  Notwithstanding anything in Section 8 of the Plan to the contrary, in the event of termination of the Participant's continued service to the Company, any DSUs that have not vested will lapse immediately.  Vested DSUs shall be settled at such time and in such form as provided in Section 3 above.

 

	
5.
	
Dilution Protection:  The Plan contains detailed provisions for adjustments in the number and price of Shares for various corporate events, such as a change in capitalization, or a corporate transaction.  

 

	
6.
	
Stockholder Rights:  The Award itself does not confer the rights of the underlying Shares, which are the subject of the Award.  Shareholder rights derive only from Share ownership, which occurs upon settlement pursuant to Section 3 above.  

 

 

Exhibit 10.6

	
7.
	
Contract:  This Agreement and the Plan constitute the entire agreement between the Participant and the Company with regard to the Award described herein, and may not be modified or amended except in a writing duly executed by the Participant and an executive officer of the Company.   

 

	
8.
	
Applicable Law:  The Plan is not subject to the Employee Retirement Income Security Act of 1974, as amended, and is not qualified under Section 401(a) of the Code.  The laws of the State of New York govern the terms and conditions of the DSUs, the Plan, and any construction or interpretation of the same.  

 

	
9.
	
Conflict:  In the event of a conflict between the provisions of this Agreement and the Plan, the Plan shall control.  A copy of the Plan is available from the Company Secretary at the Company’s U.S. headquarters. 

 

	
10.
	
Administration:  The Committee will administer the Plan.  

 

IN WITNESS WHEREOF, the Company and the Participant have executed this Agreement as of the day and year first written above.

 

AMARIN CORPORATION plc PARTICIPANT

 

By: ____________________________ Signature: ______________________________

Name: [          ]Name:[          ]

Title: [          ]amrn-ex107_219.htm

Exhibit 10.7

	
 
	
 

	

	
Renewal Agreement:

	
 
	
 

 

	
 
	
Agreement Date : 26 June 2020
	
Confirmation No : R-911513

 

	
 
	
Business Centre Details
	
 
	
Client Details

 

	
 
	
DUBLIN, Spaces South Docklands
	
 
	
Company Name
	
Amarin Pharmaceuticals Ireland Ltd

	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
Phone
	
+353 87 833 5658

	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
Email
	
tom.maher@amarincorp.com
	
 

	
 
	
 
	
 
	
 
	
 
	
 

 

				
	
Office Payment Details (exc. VAT and exc. services)

	
Office Number
	
Number of people
	
Price per Office
	
	
114
	
4
	
€ 2,115.60
	

 

	
 
	
Service Provision :
	
Start Date
	
1 October 2020
	
End Date
	
30 April 2021

	
 
	
All agreements end on the last calendar day of the month. 

 

			
	
 
	
Terms and Conditions

	
 
	
 

	
 
	
We are Regus CME Ireland Limited [the Provider], please click the link below for terms and conditions.amrn-ex108_220.htm

Exhibit 10.8

 

	
 
	
 

	

	
Renewal Agreement:

	
 
	
 

 

	
 
	
Agreement Date : August 31, 2020
	
Confirmation No : 11033770

 

	
 
	
Business Centre Details
	
 
	
Client Details

 

	
 
	
DUBLIN, Spaces South Docklands
	
 
	
Company Name
	
Amarin Pharmaceuticals Ireland Ltd

	
 
	
 
	
 
	
 

Contact Name
	
 

  Tom Maher

	
 
	
Address
	
77 Sir John Rogerson’s Quay

Block C

Grand Canal Docklands

Dublin 2

D02 VK60

Republic of Ireland

 

 
	
 
	
 

Address *

 

Town/City *

 

County/State/

Province/

Municipality

 

Post Code *

 

Country *

 

 
	
 

88 Harcourt Street

 

Dublin

 

 

 

 

 

D2

 

Republic of Ireland

	
Office Payment Details (exc. VAT and exc. services)
			

 

						
	
Office 

Number
	
Price per Person 

per Day
	
Discount on 

Initial Term
	
Discounted Price per Person per Day
	
x People
	
Discounted Price per Office per Day

	
102
	
€ 74.90
	
19.465%
	
€ 60.32
	
1
	
€ 60.32

	
103
	
€ 100.23
	
19.465%
	
€ 80.72
	
1
	
€ 80.72

 

		
	
Total Average Monthly Price per Person per Month
	
€ 2,115.65

	
Total Monthly Price
	
€ 4,231.30

 

	
 
	
Service Provision :
	
Start Date
	
September 14, 2020
	
End Date
	
April 30, 2021

	
 
	
•An Activation fee of € 40.00 per occupant will be payabe. I

•Invoices/Fees are changed on a monthly basis which is calculated based on a 30-day month I

•All agreements end on the last calendar day of the month. I

•A refundable service retainer equivalent to 2 x monthly office fee will be payable. I

 

					
	
 
	
Terms and Conditions

	
 
	
 

	
 
	
We are Regus CME Ireland Limited . This Agreement incorporates our terms of business set out on attached Terms and Conditions, attached

House Rules and Service Price Guide (where available) which you confirm you have read and understood. We both agree to comply with those

terms and our obligations as set out in them. This agreement is binding from the agreement date and may not be terminated once it is made,

except in accordance with its terms. Note that the Agreement does not come to an end automatically. See “Automatic Renewal” section of your

terms and conditions for the notice terms if you wish to end your agreement.

	
 
	
 

I accept the terms and conditions

 

Please enter your VAT number, so that we can process your order: 

 

Not VAT Registered:

 
	
 

	
 
	
Confirm by typing your name in the box below
	

 

	
        Name:   
	
Tom Maher
	
  on behalf of Amarin Pharmaceuticals Ireland Ltd
	
Signed on

August 31, 2020

 

          I confirm these details are correct to the best of my knowledge

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}]]